多不饱和脂肪酸在房颤上游治疗中的作用
摘要
目前房颤抗心律失常的治疗主要为口服抗凝剂,起搏器治疗和射频消融术,然而其中一些疗效不理想,另一些则会增加药物性心律失常或出血的风险。房颤的上游治疗可一定程度的降低新发房颤的发生率、房颤发作频率和延缓房颤发展为持续性房颤。本文旨在探讨多不饱和脂肪酸(polyunsaturated fatty acids,PUFAs)在房颤上游治疗中的作用。
出处
《牡丹江医学院学报》
2015年第6期88-90,共3页
Journal of Mudanjiang Medical University
参考文献29
-
1Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J].Eur Heart J,2010,31(19):2369-2429.
-
2Olesen JB,Torp-Pedersen C,Hansen ML,et al.The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1:a nationwide cohort study[J].Thromb Haemost,2012,107(6):1172-1179.
-
3Ferns SJ,Naccarelli GV.New oral anticoagulants:their role in stroke prevention in high-risk patients with atrial fibrillation[J].Med Clin North Am,2015,99(4):759-780.
-
4Guerra F,Shkoza M,Scappini L,et al.Omega-3 PUFAs and atrial fibrillation:have we made up our mind yet[J].Ann Noninvasive Electrocardiol,2013,18(1):12-20.
-
5任启伍,木胡牙提.心房颤动的上游治疗新进展[J].心血管病学进展,2014,35(1):91-94. 被引量:5
-
6Savelieva I,Kakouros N,Kourliouros A,et al.Upstream therapies for management of atrial fibrillation:review of clinical evidence and implications for European Society of Cardiology guidelines.Part II:secondary prevention[J].Europace,2011,13(5):610-625.
-
7Burstein B,Nattel S.Atrial fibrosis:mechanisms and clinical relevance in atrial fibrillation[J].J Am Coll Cardiol,2008,51(8):802-809.
-
8Kourliouros A,Savelieva I,Kiotsekoglou A,et al.Current concepts in the pathogenesis of atrial fibrillation[J].Am Heart J,2009,157(2):243-252.
-
9Van Wagoner DR.Oxidative stress and inflammation in atrial fibrillation:role in pathogenesis and potential as a therapeutic target[J].J Cardiovasc Pharmacol,2008,52(4):306-313.
-
10Ninio DM,Murphy KJ,Howe PR,et al.Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model[J].J Cardiovasc Electrophysiol,2005,16(11):1189-1194.
二级参考文献15
-
1Irene Savelieva,Antonios Kourliouros,John Camm.Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance[J]. Naunyn - Schmiedeberg’s Archives of Pharmacology . 2010 (3)
-
2Alejandro R. Jadad,R.Andrew Moore,Dawn Carroll,Crispin Jenkinson,D.John M. Reynolds,David J. Gavaghan,Henry J. McQuay.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?[J]. Controlled Clinical Trials . 1996 (1)
-
3YANG Shu-sen HAN Wei ZHOU Hong-yan DONG Guo WANG Bai-chun HUO Hong WEI Na CAO Yong ZHOU Guo XIU Chun-hong LI Wei-min.Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs[J].Chinese Medical Journal,2008(1):38-42. 被引量:26
-
4Alejandro Macchia,Hugo Grancelli,Sergio Varini,Daniel Nul,Nicolás Laffaye,Javier Mariani,Daniel Ferrante,Raúl Badra,Julio Figal,Silvina Ramos,Gianni Tognoni,Hernán C. Doval.Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation[J].Journal of the American College of Cardiology.2013
-
5Federico Guerra,Matilda Shkoza,Lorena Scappini,Laura Roberti,Alessandro Capucci.Omega‐3 PUFAs and Atrial Fibrillation: Have We Made Up Our Mind Yet?[J].Annals of Noninvasive Electrocardiology.2012(1)
-
6Gregory YH Lip,Hung Fat Tse,Deirdre A Lane.Atrial fibrillation[J].The Lancet.2012(9816)
-
7Savina Nodari,Marco Triggiani,Umberto Campia,Alessandra Manerba,Giuseppe Milesi,Bruno M. Cesana,Mihai Gheorghiade,Livio Dei Cas.n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion: A Prospective, Randomized Study[J].Circulation.2011(10)
-
8Saurabh Kumar,Fiona Sutherland,Andrew W. Teh,Patrick M. Heck,Geoffrey Lee,Manohar L. Garg,Paul B. Sparks.Effects of Chronic Omega-3 Polyunsaturated Fatty Acid Supplementation on Human Pulmonary Vein and Left Atrial Electrophysiology in Paroxysmal Atrial Fibrillation[J].The American Journal of Cardiology.2011(4)
-
9Shaojie Chen,Ying Dong,Jinqi Fan,Yuehui Yin.Rate vs. rhythm control in patients with atrial fibrillation — An updated meta-analysis of 10 randomized controlled trials[J].International Journal of Cardiology.2011(1)
-
10Masao Sakabe,Akiko Shiroshita-Takeshita,Ange Maguy,Chloe Dumesnil,Anil Nigam,Tack-Ki Leung,Stanley Nattel.Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling[J].Circulation.2007(19)
共引文献7
-
1马征,曲信彦,胡敏勇,李波.参连复脉颗粒对心房颤动大鼠心电图及炎症反应与氧化应激的影响[J].新中医,2023,55(13):1-6.
-
2林希,梁兆光.心房颤动的上游治疗进展[J].现代中西医结合杂志,2015,24(23):2620-2622. 被引量:2
-
3陈绍成,苏丽珍.心房纤颤的非药物治疗研究进展[J].甘肃医药,2017,36(6):434-436. 被引量:1
-
4李建华,贾晓萌,侯应龙.心房颤动的现代治疗概况[J].中国心脏起搏与心电生理杂志,2017,31(6):572-575. 被引量:5
-
5周明荣.心房颤动612例临床分析[J].智慧健康,2018,4(2):39-40. 被引量:1
-
6刘松涛,罗潇,李萍.心房颤动上游治疗的研究进展[J].中华全科医学,2018,16(11):1886-1889. 被引量:10
-
7冯磊,王文玉,王中华,张春雨,刘晓辉.螺内酯对高龄阵发性房颤并心力衰竭患者心功能的影响研究[J].中国现代药物应用,2022,16(7):81-83.
-
1徐楷,刘旭.心房颤动的社区管理[J].上海医药,2014,35(16):3-5. 被引量:1
-
2顾俊,胡伟,刘旭.心房重构研究进展[J].国际心血管病杂志,2014,41(6):398-401. 被引量:9
-
3陈济明,潘大彬.缝隙连接重塑与心律失常上游治疗[J].承德医学院学报,2016,33(5):432-436. 被引量:3
-
4林希,梁兆光.心房颤动的上游治疗进展[J].现代中西医结合杂志,2015,24(23):2620-2622. 被引量:2
-
5刘靖,刘达兴.心房颤动的治疗进展[J].西部医学,2013,25(10):1593-1595. 被引量:4
-
6袁跃龙,毛万里,李峙澄.基层医院住院心房颤动患者609例回顾性分析[J].重庆医学,2013,42(23):2783-2784. 被引量:5
-
7庄端蓉,陈颖敏.他汀类药物作为心房颤动上游治疗的研究状况[J].中国心脏起搏与心电生理杂志,2012,26(5):441-443. 被引量:6
-
8马跃东,马虹.心房颤动的上游治疗进展[J].临床心电学杂志,2012,21(4):292-294. 被引量:2
-
9侯鹏,王辉山.炎症与心房颤动相关性的研究进展[J].中国胸心血管外科临床杂志,2016,23(1):72-77. 被引量:3
-
10王禹川,丁燕生.心律失常的“上游治疗”[J].心血管病学进展,2012,33(3):304-307. 被引量:1